Show simple item record

dc.contributor.authorMukherjee, S.
dc.contributor.authorHurt, C.
dc.contributor.authorRadhakrishna, Ganesh
dc.contributor.authorGwynne, S.
dc.contributor.authorBateman, A.
dc.contributor.authorGollins, S.
dc.contributor.authorHawkins, M. A.
dc.contributor.authorCanham, J.
dc.contributor.authorGrabsch, H. I.
dc.contributor.authorFalk, S.
dc.contributor.authorSharma, R. A.
dc.contributor.authorRay, R.
dc.contributor.authorRoy, R.
dc.contributor.authorCox, C.
dc.contributor.authorMaynard, N.
dc.contributor.authorNixon, L.
dc.contributor.authorSebag-Montefiore, D. J.
dc.contributor.authorMaughan, T.
dc.contributor.authorGriffiths, G. O.
dc.contributor.authorCrosby, T. D. L.
dc.date.accessioned2021-09-30T11:56:08Z
dc.date.available2021-09-30T11:56:08Z
dc.date.issued2021en
dc.identifier.citationMukherjee S, Hurt C, Radhakrishna G, Gwynne S, Bateman A, Gollins S, et al. Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. European Journal of Cancer. 2021 Aug;153:153–61.en
dc.identifier.pmid34157617en
dc.identifier.doi10.1016/j.ejca.2021.05.020en
dc.identifier.urihttp://hdl.handle.net/10541/624623
dc.description.abstractAim: This is the first randomised study to evaluate toxicity and survival outcomes of two neoadjuvant chemoradiotherapy (CRT) regimens for patients with localised oesophageal adenocarcinoma (OAC) or gastro-oesophageal junction (GOJ) adenocarcinoma. The initial results showed comparable toxicity between regimens and pathological complete response (pCR) rate favouring CarPacRT. Herein, we report survival, progression patterns, and long-term toxicity after a median follow-up of 40.7 months. Methods: NeoSCOPE was an open-label, UK multicentre, randomised, phase II trial. Eighty-five patients with resectable OAC or GOJ adenocarcinoma, ≥cT3 and/or ≥cN1 (TNM v7), suitable for neoadjuvant CRT, were recruited between October 2013 and February 2015. Patients were randomised to OxCapRT (oxaliplatin 85 mg/m2 on Days 1, 15, and 29; capecitabine 625 mg/m2 orally twice daily on days of radiotherapy [RT]) or CarPacRT (carboplatin AUC2; paclitaxel 50 mg/m2 on Days 1, 8, 15, 22, and 29). RT dose was 45 Gy/25 fractions/5 weeks. Both arms received induction chemotherapy (two cycles oxaliplatin 130 mg/m2 on Day 1, capecitabine 625 mg/m2 orally twice daily on Days 1-21) before CRT. Surgery was performed 6-8 weeks after CRT. The primary end-point was pCR. Secondary end-points were toxicity, progression-free survival (PFS), overall survival (OS), and patterns of progression. Results: Eighty-five patients were recruited from 17 UK centres. The median OS was 41.7 months (95% confidence interval [CI] 19.6 to not reached) in the OxCapRT arm and was not reached in the CarPacRT arm (multivariable hazard ratio [HR] = 0.48, 95% CIs: 0.24-0.95, P = 0.035). The median PFS was 32.6 months (95% CIs: 17.1 to not reached) in the OxCapRT arm and was not reached in the CarPacRT arm (multivariable HR = 0.54, 95% CIs: 0.29-1.01, P = 0.053). In both arms, the distant progression was twice as common as locoregional progression. Conclusions: OS and PFS favoured neoadjuvant CarPacRT over OxCapRT. Distant was more common than locoregional progression; therefore, priority should be given to optimising the systemic treatment component.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.ejca.2021.05.020en
dc.titleOxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trialen
dc.typeArticleen
dc.contributor.departmentOxford Institute for Radiation Oncology, Oxford University, Oxforden
dc.identifier.journalEuropean Journal of Canceren
dc.description.noteen]
refterms.dateFOA2021-10-13T08:57:41Z


Files in this item

Thumbnail
Name:
34157617.pdf
Size:
800.3Kb
Format:
PDF
Description:
From CORE

This item appears in the following Collection(s)

Show simple item record